Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zdenko Huťka"'
Autor:
Marian Grendar, Anna Farkasova, Zuzana Kviatkovská, Lukáš Plank, Alena Liskova, Zdenko Huťka, Vladimír Tancoš
Publikováno v:
Journal of Clinical Pathology. 75:373-378
AimsPulmonary squamous cell carcinoma (SqCC) represents the second most common non-small cell lung carcinoma type. The mechanisms which regulate programmed death ligand 1 (PD-L1) expression in this form of lung cancer are not fully elucidated yet.Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615880381850a783cbd41bec160a376a
https://doi.org/10.1136/jclinpath-2020-207171
https://doi.org/10.1136/jclinpath-2020-207171
Autor:
Zdenko Huťka, Zuzana Kviatkovská, Lukáš Plank, Anna Farkasova, Vladimír Tancoš, Marian Grendar
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 33(1)
Background Immunotherapy blocking the PD-1/PD-L1 signalling pathway has become a dominant treatment modality for patients with non-small cell lung carcinoma (NSCLC). Programmed death-ligand 1 (PD-L1) expression on the membrane of tumour cells and/or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab739e062e19ee769eea01c063f3e8a
https://pubmed.ncbi.nlm.nih.gov/32075390
https://pubmed.ncbi.nlm.nih.gov/32075390
Autor:
Vladimír Tancoš, Anna Farkasova, Marian Grendar, Zuzana Kviatkovská, Jozef Mičák, Timothy C. Hardman, Zdenko Huťka, Gareth A.D. Hardy, Lukáš Plank
Publikováno v:
Pathology. 52(5)
Intratumoural heterogeneity of pulmonary adenocarcinoma challenges the accurate interpretation of programmed death ligand 1 (PD-L1) immunohistochemistry, which is the only validated predictive marker for successful anti-PD-1/PD-L1 immunotherapy. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1358e7634181bc68f45c731b08de8a
https://pubmed.ncbi.nlm.nih.gov/32586689
https://pubmed.ncbi.nlm.nih.gov/32586689
Autor:
Anna, Farkašová, Vladimír, Tancoš, Zuzana, Kviatkovská, Zdenko, Huťka, Jozef, Mičák, Karla, Scheerová, Peter, Szépe, Lukáš, Plank
Publikováno v:
Ceskoslovenska patologie. 54(3)
Recent studies on check-point inhibitor therapy, which seems to improve the prognosis of patients with advanced non-small cell lung carcinoma increase the importance of immunohistochemical analyses of the programmed-death receptor and of its ligand,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19711e6796f2ddccc8767214580a8826
https://pubmed.ncbi.nlm.nih.gov/30445818
https://pubmed.ncbi.nlm.nih.gov/30445818
Autor:
Dzian A; Comenius University, Jessenius Faculty of Medicine in Martin. anton.dzian@gmail.com., Ivan F, Zdenko H, Peter S
Publikováno v:
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace [Monaldi Arch Chest Dis] 2017 Dec 14; Vol. 87 (3), pp. 797. Date of Electronic Publication: 2017 Dec 14.